Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of E7777 Prior to Kymriah for R/R DLBCL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04855253
Recruitment Status : Recruiting
First Posted : April 22, 2021
Last Update Posted : July 14, 2021
Sponsor:
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota

Brief Summary:
This is a single institution Phase I study to determine the maximum tolerated dose (MTD) of E7777 when given prior to cyclophosphamide/fludarabine (CY/Flu) lymphodepletion (LD) chemotherapy and Kymriah, a commercial tisagenlecleucel product, for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are at a higher risk for failure of CAR-T therapy.

Condition or disease Intervention/treatment Phase
DLBCL Diffuse Large B Cell Lymphoma High-grade B-cell Lymphoma DLBCL Arising From Follicular Lymphoma Drug: E7777 Phase 1 Phase 2

Detailed Description:
E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. This trial is designed to augment lymphodepletion prior to CAR-T cells by administration of a targeted immunotoxin against CD25-expressing T-cells. CD25 is expressed at high levels on Tregs but also on activated effector T cells. The use of the CAR-T cell product and associated apheresis and LD chemotherapy is considered standard of care (SOC).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

The Phase I study consists of two components: dose finding to establish a maximum tolerated dose (MTD) of E7777 and a small extension component to provide an estimate of efficacy at the MTD.

A single dose of E7777 is given on Day -7, two days prior to the start of lymphodepleting chemotherapy. Up to 3 dose levels will be tested. The MTD is determined by using the continual reassessment method (CRM). Enrollment begins with Dose Level 1 using a cohort of two patients. Twenty one (21) days after the 2nd patient's tisagenlecleucel infusion the next cohort of 2 patients are assigned to the most appropriate strategy based on updated toxicity probabilities corresponding to the desired maximum toxicity rate of ≤ 25% as determined by the study statistician (or designee). Enrollment continues in cohorts of 2 separated by a minimum of 28 days until 20 patients are enrolled or 10 sequential patients are enrolled at the same dose level. No intra-cohort staggering is required.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Trial Using E7777 to Enhance Regulatory T-Cell Depletion Prior to Tisagenlecleucel (Kymriah) Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Actual Study Start Date : June 9, 2021
Estimated Primary Completion Date : December 2024
Estimated Study Completion Date : December 2024


Arm Intervention/treatment
Experimental: Dose level 1 : E7777 at 5 mcg/kg
Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
Drug: E7777
E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.

Experimental: Dose level 1 : E7777 at 7 mcg/kg
Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
Drug: E7777
E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.

Experimental: Dose level 1 : E7777 at 9 mcg/kg
Single dose of E7777 given on Day -7 two days prior to the start of lymphodepleting chemotherapy
Drug: E7777
E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.

Experimental: MTD from phase 1
Single dose of E7777 (Maximum tolerated dose level identified in phase 1) given on Day -7 two days prior to the start of lymphodepleting chemotherapy
Drug: E7777
E7777 is a recombinant fusion toxin consisting of full-length human IL-2 fused to the catalytic domains of diphtheria toxin. E7777 is preferentially bound to and internalized by cells expressing the high affinity form (CD25+) of the IL-2 receptor.




Primary Outcome Measures :
  1. Number of participants experiencing dose limiting toxicity events [ Time Frame: 28 Days Post E7777 infusion ]

    Dose Limiting Toxicity (DLT) is defined as any of the following events based on CTCAE v5 from the 1st infusion of E7777 through 21 days after the administration of tisagenlecleucel (~28 days after E7777).

    • Grade 4 infusion related reaction (IRR) associated with E7777
    • Grade 4 or Grade 3 capillary leak syndrome (CLS)
    • Grade 3 or 4 liver function test abnormality that do not resolve to <Grade 2 within 5 days
    • Grade 3 or 4 non-hematologic toxicity event that occurs after the administration of E7777 and before lymphodepleting therapy
    • Any adverse event that results in a delay of lymphodepleting therapy for more than 72 hours and attributed to E7777
    • Any Grade 5 adverse event


Secondary Outcome Measures :
  1. Number of participants experiencing adverse events [ Time Frame: 100 days Post E7777 infusion ]
    Number of participants experiencing adverse events related to E7777 to determine safety of the E7777

  2. Number of participants experiencing disease free survival (DFS) [ Time Frame: 1 year Post E7777 infusion ]
    Number of participants experiencing disease free survival (DFS) at 1 year

  3. Number of participants experiencing overall survival (OS) [ Time Frame: 1 year Post E7777 infusion ]
    Number of participants experiencing overall survival (DFS) at 1 year

  4. Number of non-relapse mortality incidents at day 100 [ Time Frame: 100 days Post E7777 infusion ]
    Number of participants experiencing non-relapse mortality at day 100 post E7777 infusion

  5. Number of Grade 3 or 4 cytokine release syndrome (CRS) incidents [ Time Frame: 28 Days Post E7777 infusion ]
    Number of participants experiencing Grade 3 or 4 cytokine release syndrome (CRS) after tisagenlecleucel therapy.

  6. Number of Grade 3 or 4 immune effector cell associated neurotoxicity (ICAN) syndrome incidents [ Time Frame: 28 Days Post E7777 infusion ]
    Number of participants experiencing Grade 3 or 4 immune effector cell associated neurotoxicity (ICAN) syndrome after tisagenlecleucel therapy.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of a relapse or refractory (r/r) large B cell lymphoma, for which treatment with Kymriah is planned, including:

    • diffuse large B-cell lymphoma (DLBCL) not otherwise specified,
    • high grade B-cell lymphoma
    • DLBCL arising from follicular lymphoma
  • Considered at high risk for progression after CAR-T therapy by meeting one or more of the following factors:

    • refractory to last line of therapy
    • myc over expression >40% in any prior biopsy
    • ≥2 sites of extranodal disease
  • Received two or more lines of systemic therapy
  • Has secured insurance coverage for Kymriah administration either in the outpatient or inpatient setting.
  • Age 18 years or older at the time of signing consent.
  • ECOG performance status of 0, 1, or 2
  • Adequate bone marrow reserve defined as:

    • Absolute neutrophil count (ANC) > 1,000/mm^3
    • Platelets ≥ 50,000/mm^3 (transfusion support can be provided)
    • Hemoglobin >8.0 mg/dl (transfusion support can be provided) Bone marrow involvement at disease assessment is an exclusion as these patients are at an increased risk of severe CRS and/or neurotoxicity
  • Adequate organ function at enrollment and within 14 days of planned E7777 treatment including:

    • renal function: eGFR ≥ 50 mL/min/1.73 m^2
    • liver function: ALT ≤ 3 times the upper limit of normal (ULN) for age, AST ≤ 3 times the ULN, total bilirubin ≤ 2.0 mg/dl with the exception of patients with Gilbert syndrome; may be included if their total bilirubin is ≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN (if liver is involved by lymphoma, the exception are allowed upon approval of PI)
    • albumin ≥ 3.0 g/dl
  • Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea (CTCAE v5) and pulse oxygenation SpO2 > 91% on room air. Pulmonary function tests within 28 days of enrollment: >50% corrected DLCO and FEV1
  • Hemodynamically stable and LVEF ≥ 50% confirmed by echocardiogram or MUGA
  • Life expectancy ≥12 weeks in the opinion of the enrolling investigator as documented in the medical record
  • Women of child bearing potential and sexually active males with partners of child bearing potential must agree to use birth control for at least 30 days after study treatment or at least at least 4 months after the final dose of CY, whichever is longer Female participants: Two forms of birth control, one of which must be a barrier method, for example: use of intrauterine device (IUD) or oral contraceptives, plus a barrier method such as a condom, diaphragm or cervical cap Male participants: If possible to father a child (unless a successful vasectomy with confirmed azoospermia) participant and female partner, must use adequate contraception
  • Written voluntary consent prior to the performance of any research related tests or procedures

Exclusion Criteria:

  • Pregnant or breastfeeding - Females of childbearing potential must have a blood test or urine study within 14 days prior to study enrollment to rule out pregnancy. All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)
  • Known bone marrow involvement, if history of bone marrow involvement must have a BM biopsy to rule-out current involvement
  • Prior allogeneic transplant
  • Ocular disease or complaints visual acuity impairment, color or shape distortion, or blurred vision - potential participants are required to have an ophthalmological examine as part of screening
  • Known CNS involvement by malignancy - if clinically suspicious, must be ruled-out by examination of cerebrospinal fluid (CSF) by flow cytometry
  • Uncontrolled active hepatitis B or hepatitis C
  • Active or inactive HIV infection
  • Untreated active bacterial, viral or fungal infection (e.g. blood culture positive ≤ 72 hours prior to enrollment)
  • History of heart failure or pulmonary edema, evidence of pleural effusion or active lower extremity edema
  • Uncontrolled unstable angina and/or myocardial infarction within 3 months of enrollment
  • Investigational medicinal product within the last 7 days prior to apheresis or CAR-T infusion

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04855253


Contacts
Layout table for location contacts
Contact: Cancer Center Clinical Trials Office 612-676-4200 ccinfo@umn.edu

Locations
Layout table for location information
United States, Minnesota
University of Minnesota, Masonic Cancer Center Recruiting
Minneapolis, Minnesota, United States, 55455
Principal Investigator: Murali Janakiram, MD         
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Investigators
Layout table for investigator information
Principal Investigator: Murali Janakiram, MD Masonic Cancer Center, University of Minnesota
Layout table for additonal information
Responsible Party: Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier: NCT04855253    
Other Study ID Numbers: 2020LS100
MT2020-27 ( Other Identifier: University of Minnesota Masonic Cancer Center )
First Posted: April 22, 2021    Key Record Dates
Last Update Posted: July 14, 2021
Last Verified: July 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin